Fresenius Medical Care published form 20-F for the fiscal year 2024
02/25/2025 | Press release
Bad Homburg (February 25, 2025) - Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, has filed the annual report 2024 on form 20-F ## Article Body Fresenius Medical Care published form 20-F for the fiscal year 2024 02/25/2025 | Press release Bad Homburg (February 25, 2025) - Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, has filed the annual report 2024 on form 20-F with the U.S. Securities and Exchange Commission (SEC). The report is available at the company’s website in the “Investors” section as well as at the SEC's website (www.sec.gov). A hard copy of Fresenius Medical Care’s annual report on form 20-F including the complete audited consolidated financial statements may be obtained from the Company free of charge upon request to the company’s Investor Relations department by email at ir@freseniusmedicalcare.com. About Fresenius Medical Care: Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,675 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 299,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS). Disclaimer: This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various risk factors and uncertainties, including, but not limited to, changes in business, economic or competitive conditions, changes in reimbursement, regulatory compliance issues, regulatory reforms, results of clinical studies, foreign exchange rate and interest rate fluctuations, uncertainties in litigation or investigative proceedings, cyber security issues and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release. Back To top: ## Recent Company News - 2026-07-29 07:00 EST — [Fresenius Medical Care announces BEACON-US, generating real-world evidence supporting high-volume hemodiafiltration for U.S. dialysis patients](https://biopharmsignal.com/news/FMS/fresenius-medical-care-announces-beacon-us-generating-real-world-evidence-suppor-8547f5f8) — Source: Fresenius Medical Care Ventures - 2026-07-20 07:00 EST — [Fresenius Medical Care introduces TherapyWise™ analytics for kidney replacement therapy](https://biopharmsignal.com/news/FMS/fresenius-medical-care-introduces-therapywise-analytics-for-kidney-replacement-t-6fa82f2a) — Source: Fresenius Medical Care Ventures - 2026-06-10 07:00 EST — [Interwell Health Delivers Strong Quality Scores and Shared Savings in CMS Value-Based Kidney Care Model](https://biopharmsignal.com/news/FMS/interwell-health-delivers-strong-quality-scores-and-shared-savings-in-cms-value--e2c55e86) — Source: Fresenius Medical Care Ventures - 2026-06-03 07:00 EST — [Fresenius Medical Care launches kinexus worldwide, a unified digital platform to support home dialysis](https://biopharmsignal.com/news/FMS/fresenius-medical-care-launches-kinexus-worldwide-a-unified-digital-platform-to-support-home-dialysis) — Source: Fresenius Medical Care Ventures - 2026-05-28 07:00 EST — [Fresenius Medical Care launches first tranche of its share buyback program of up to EUR 600 million](https://biopharmsignal.com/news/FMS/fresenius-medical-care-launches-first-tranche-of-its-share-buyback-program-of-up-to-eur-600-million) — Source: Fresenius Medical Care Ventures ## Related News - 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9) - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922) - 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c) - 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)